Cybin Inc. announced that the U.S. Food and Drug Administration (?FDA?) has cleared its investigational new drug (?IND?) application for CYB004, its proprietary deuterated dimethyltryptamine (?DMT?) molecule in development for the treatment of Generalized Anxiety Disorder (?GAD?). This clearance allows the Company to proceed with its plans to initiate a Phase 2a study of CYB004 in First Quarter 2024. The Phase 2a study will be a randomized, double-blind, active-controlled trial to assess the preliminary clinical efficacy, safety, tolerability, PK and PD of CYB004 in participants with GAD.

This trial will be conducted at study sites in the United States.